Querying GLEIF's public Legal Entity Identifier (LEI) data — 3,370,711 entity records and 525,667 ownership-relationship records, — turns up a number that undercuts the system's own headline claim: only 139,513 entities (4.1%) in the full LEI population carry an actual, machine-readable parent-consolidation edge (IS_DIRECTLY_CONSOLIDATED_BY or IS_ULTIMATELY_CONSOLIDATED_BY). GLEIF's Q4 2025 business report advertises that 99% of registrants "report" parent information — but reporting an attestation and publishing a verifiable relationship record are two different things, and for corporate-structure diligence on pharma licensing or M&A targets, only the second one is usable.
What we actually found for a real company
We pulled every LEI-registered entity with "Pfizer" in its legal name (171 entities, spanning Luxembourg, Ireland, the Netherlands, India, Belgium and the US) and walked their relationship edges. Of those 171, close to two-thirds carry a published consolidation record, and every one that does resolves — sometimes through an intermediate Luxembourg holding company — to the same ultimate parent node: LEI 765LHXWGK1KXCLTFYQ30, PFIZER INC. (US). For example, PFIZER POLSKA SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ (Poland) is IS_DIRECTLY_CONSOLIDATED_BY PFIZER LUXEMBOURG SARL — an intermediate Luxembourg holding entity — while simultaneously carrying an IS_ULTIMATELY_CONSOLIDATED_BY edge straight to Pfizer Inc. — a chain that, absent LEI, would otherwise require pulling SEC Exhibit 21 subsidiary lists or national corporate registries one jurisdiction at a time. Public reporting on Pfizer's structure (via SEC Exhibit 21 filings and investigative journalism on its Dutch CV holding umbrella, C.P. Pharmaceuticals International C.V.) confirms dozens of Irish and Luxembourg intermediate entities sit between operating subsidiaries and the US parent — exactly the multi-hop pattern the relationship graph reconstructs.
Why the gap exists
The Global LEI System's Level 2 ("who owns whom") data was built primarily to satisfy financial-market reporting rules — MiFID II/EMIR-style transaction reporting — not general corporate-registry completeness. An entity that never trades a reportable financial instrument has weak incentive to file a verified relationship record, and can instead file a "no known person" reporting exception, which the public relationship data does not carry as a linked record. That means the entities that DO show up with a parent link skew toward companies active in capital markets: exactly the multinational pharma and biotech issuers, not the thousands of small CROs, API suppliers, or single-site device makers that licensing teams also need to screen. Separately, 104,090 of 525,667 relationship records (19.8%) are marked LAPSED rather than currently published — relationship records require renewal on a different cycle than the underlying entity record, so a subsidiary can have an up-to-date LEI while its parent link quietly expires.
Why this matters
For cross-border licensing and supplier diligence, LEI relationship data is one of the only free, standardized, machine-readable views into "who ultimately controls this entity" — useful as a first-pass screen before falling back to national registries or paid corporate databases. But treat an absent relationship edge as inconclusive, not as evidence of a flat ownership structure: it may simply mean the parent link was never worth filing, or has lapsed since its last renewal.